You are here

MIT Study: Prices of Cancer Drugs Have Soared Since 1995

Researchers find 10% annual increase, after inflation

The prices of leading cancer drugs have risen at rates far outstripping inflation over the last two decades, according to a new study published in the Journal of Economic Perspectives –– but the exact reasons for the cost increases are unclear.

Since 1995, a group of 58 leading cancer drugs has increased in price by 10% annually, even when adjusted for inflation and incremental health benefits, the study finds. More specifically, in 1995, cancer drugs in this group cost approximately $54,100 for each year of life that they were estimated to add; by 2013, such drugs cost about $207,000 per each additional year of life.

Those increases have sparked criticism in recent years from doctors, among other groups, who have questioned the pricing of major drugs. But the empirical results may also show, the researchers say, that rising price levels reflect a greater social tolerance for significant health-care costs.

“I think the value of good health has really increased enormously over the last few decades,” says co-author Dr. Ernst Berndt, a professor at the Massachusetts Institute of Technology (MIT) Sloan School of Management. “We treasure it and are willing to pay a fair bit for that.”

The paper notes that there have been some cases of political backlash in recent years –– in Oregon, for instance –– in response to proposed policies that would limit the ability of public insurance programs to buy expensive, life-extending cancer drugs. On the other hand, as the authors observe, patient cost-sharing in medical plans has also increased since 1995, limiting the extent to which demand can explain the changes.

Patients do seem to be paying for improved quality, to an extent: the study found a positive correlation between the effectiveness of drugs and their prices. Cancer drug prices increase approximately 120% for each additional year of life gained by a patient.

“We found that the greater the improvement of the drug over the existing therapies, the higher the price,” Berndt explains. “So price was related to quality –– but price increased more than did quality.”

So what else is driving prices?

Globally, cancer drugs are the class of pharmaceuticals with the highest sales, at $91 billion in 2013; $37 billion of that spending was in the U.S. As in many major global markets, there is contention about what price levels are justified. The paper notes that in 2013, a group of 100 prominent oncologists claimed that drug companies’ pricing policies involved a “simple formula: start with the price of the most recent similar drug on the market and price the new one within 10 to 20 percent of that price (usually higher).”

The paper notes that such assertions are at least consistent with “reference price models of demand,” in which consumers’ decisions to pay involve existing prices rather than a measurement of intrinsic value. Berndt says such challenges are “probably credible,” but notes that it is hard to assess how much money pharmaceutical companies have spent developing specific drugs.

“Typically, drug companies and biotech companies simultaneously study all sorts of medicines,” Berndt notes. Therefore, he says, “It's extremely difficult to allocate historical costs of drug development to specific new drugs.”

Some additional factors may be entering into the cost of cancer therapeutics today. The paper notes that the “340B” pricing program enacted by Congress in 1992 requires discounts for some hospitals and clinics, which may incentivize companies to raise prices to compensate.

Overall, the authors conclude: “We believe the direction of causation runs from prices to research and development costs –– as prices increase, manufacturers are willing to spend more to discover new drugs –– rather than the other way around.”

Source: MIT; March 18, 2015.

Recent Headlines

Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs